526 related articles for article (PubMed ID: 34506743)
1. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Lancet; 2021 Nov; 398(10312):1713-1725. PubMed ID: 34506743
[TBL] [Abstract][Full Text] [Related]
2. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study.
European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration
Lancet; 2024 Jan; 403(10421):55-66. PubMed ID: 38101429
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
[TBL] [Abstract][Full Text] [Related]
4. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
[TBL] [Abstract][Full Text] [Related]
5. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
[TBL] [Abstract][Full Text] [Related]
6. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
[TBL] [Abstract][Full Text] [Related]
7. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
[TBL] [Abstract][Full Text] [Related]
8. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
[TBL] [Abstract][Full Text] [Related]
9. Overview of a collaborative global effort to address the burden of familial hypercholesterolaemia.
Lyons ARM; Stevens CAT; Dharmayat KI; Vallejo-Vaz DAJ; Ray KK
Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S113-S116. PubMed ID: 37981086
[TBL] [Abstract][Full Text] [Related]
10. Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia.
Ibrahim S; Reeskamp LF; de Goeij JN; Hovingh GK; Planken RN; Bax WA; Min JK; Earls JP; Knaapen P; Wiegman A; Stroes ESG; Nurmohamed NS
Eur J Prev Cardiol; 2024 May; 31(7):892-900. PubMed ID: 38243822
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of people with familial hypercholesterolaemia in a Belgian lipid clinic.
Ide V; De Cock D; Pazmino S; Vangoitsenhoven R; Van der Schueren B; Mertens A
Acta Cardiol; 2024 Feb; 79(1):58-67. PubMed ID: 37882513
[TBL] [Abstract][Full Text] [Related]
12. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study.
Alonso R; Arroyo-Olivares R; Muñiz-Grijalvo O; Díaz-Díaz JL; Muñoz-Torrero JS; Romero MJ; de Andrés R; Zambón D; Mañas MD; Fuentes-Jiménez F; Aguado R; Alvarez-Baños P; Arrieta F; Gonzalez-Bustos P; Cepeda J; Martin-Ordiales M; Mosquera D; Michan A; de Isla LP; Argueso R; Mata P
Eur J Prev Cardiol; 2023 Mar; 30(4):320-328. PubMed ID: 36416136
[TBL] [Abstract][Full Text] [Related]
13. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International ChoLesterol management Practice Study.
Blom DJ; Almahmeed W; Al-Rasadi K; Azuri J; Daclin V; Kayikcioglu M; Mercier F; Ruiz AJ; Santos RD;
J Clin Lipidol; 2019; 13(4):594-600. PubMed ID: 31208705
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
[TBL] [Abstract][Full Text] [Related]
16. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
; Vallejo-Vaz AJ; De Marco M; Stevens CAT; Akram A; Freiberger T; Hovingh GK; Kastelein JJP; Mata P; Raal FJ; Santos RD; Soran H; Watts GF; Abifadel M; Aguilar-Salinas CA; Al-Khnifsawi M; AlKindi FA; Alnouri F; Alonso R; Al-Rasadi K; Al-Sarraf A; Ashavaid TF; Binder CJ; Bogsrud MP; Bourbon M; Bruckert E; Chlebus K; Corral P; Descamps O; Durst R; Ezhov M; Fras Z; Genest J; Groselj U; Harada-Shiba M; Kayikcioglu M; Lalic K; Lam CSP; Latkovskis G; Laufs U; Liberopoulos E; Lin J; Maher V; Majano N; Marais AD; März W; Mirrakhimov E; Miserez AR; Mitchenko O; Nawawi HM; Nordestgaard BG; Paragh G; Petrulioniene Z; Pojskic B; Postadzhiyan A; Reda A; Reiner Ž; Sadoh WE; Sahebkar A; Shehab A; Shek AB; Stoll M; Su TC; Subramaniam T; Susekov AV; Symeonides P; Tilney M; Tomlinson B; Truong TH; Tselepis AD; Tybjærg-Hansen A; Vázquez-Cárdenas A; Viigimaa M; Vohnout B; Widén E; Yamashita S; Banach M; Gaita D; Jiang L; Nilsson L; Santos LE; Schunkert H; Tokgözoğlu L; Car J; Catapano AL; Ray KK;
Atherosclerosis; 2018 Oct; 277():234-255. PubMed ID: 30270054
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
19. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration.
; Vallejo-Vaz AJ; Akram A; Kondapally Seshasai SR; Cole D; Watts GF; Hovingh GK; Kastelein JJ; Mata P; Raal FJ; Santos RD; Soran H; Freiberger T; Abifadel M; Aguilar-Salinas CA; Alnouri F; Alonso R; Al-Rasadi K; Banach M; Bogsrud MP; Bourbon M; Bruckert E; Car J; Ceska R; Corral P; Descamps O; Dieplinger H; Do CT; Durst R; Ezhov MV; Fras Z; Gaita D; Gaspar IM; Genest J; Harada-Shiba M; Jiang L; Kayikcioglu M; Lam CS; Latkovskis G; Laufs U; Liberopoulos E; Lin J; Lin N; Maher V; Majano N; Marais AD; März W; Mirrakhimov E; Miserez AR; Mitchenko O; Nawawi H; Nilsson L; Nordestgaard BG; Paragh G; Petrulioniene Z; Pojskic B; Reiner Ž; Sahebkar A; Santos LE; Schunkert H; Shehab A; Slimane MN; Stoll M; Su TC; Susekov A; Tilney M; Tomlinson B; Tselepis AD; Vohnout B; Widén E; Yamashita S; Catapano AL; Ray KK
Atheroscler Suppl; 2016 Dec; 22():1-32. PubMed ID: 27939304
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
